PuSH - Publication Server of Helmholtz Zentrum München

Hoeper, M.M.* ; Pausch, C.* ; Grünig, E.* ; Klose, H.* ; Staehler, G.* ; Huscher, D.* ; Pittrow, D.* ; Olsson, K.M.* ; Vizza, C.D.* ; Gall, H.* ; Benjamin, N.* ; Distler, O.* ; Opitz, C.* ; Gibbs, J.S.R.* ; Delcroix, M.* ; Ghofrani, H.A.* ; Rosenkranz, S.* ; Ewert, R.* ; Kaemmerer, H.* ; Lange, T.J.* ; Kabitz, H.J.* ; Skowasch, D.* ; Skride, A.* ; Jureviciene, E.* ; Paleviciute, E.* ; Miliauskas, S.* ; Claussen, M.* ; Behr, J. ; Milger, K.* ; Halank, M.* ; Wilkens, H.* ; Wirtz, H.* ; Pfeuffer-Jovic, E.* ; Harbaum, L.* ; Scholtz, W.* ; Dumitrescu, D.* ; Bruch, L.* ; Coghlan, G.* ; Neurohr, C.* ; Tsangaris, I.* ; Gorenflo, M.* ; Scelsi, L.* ; Vonk-Noordegraaf, A.* ; Ulrich, S.* ; Held, M.*

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.

J. Heart Lung Transpl. 39, 1435-1444 (2020)
Publ. Version/Full Text Research data DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Cluster ; Mortality ; Phenotypes ; Pulmonary Arterial Hypertension ; Survival; Diffusion Capacity; Heart-failure; Survival; Capillary; Diagnosis
ISSN (print) / ISBN 1053-2498
e-ISSN 1557-3117
Journal Journal of Heart and Lung Transplantation, The
Quellenangaben Volume: 39, Issue: 12, Pages: 1435-1444 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Lung Health and Immunity (LHI)
Grants GSK
OMT
Bayer
Actelion Pharmaceuticals
Acceleron
German Centre of Lung Research (DZL)